Your browser doesn't support javascript.
loading
Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study.
Bahaa, Mostafa M; Hegazy, Sahar K; Maher, Maha M; Bahgat, Monir M; El-Haggar, Sahar M.
Afiliación
  • Bahaa MM; Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt. mostafabahaamnf@gmail.com.
  • Hegazy SK; Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.
  • Maher MM; Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Bahgat MM; Internal Medicine Department, Faculty of Medicine, Horus University, New Damietta, Egypt.
  • El-Haggar SM; Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Inflammopharmacology ; 2024 Aug 27.
Article en En | MEDLINE | ID: mdl-39192162
ABSTRACT

BACKGROUND:

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that lasts a long time and has a variety of causes.

AIM:

The primary aim of this study was to evaluate pentoxifylline's (PTX) essential function in patients with UC.

METHODS:

Fifty-two mild to moderate UC patients who matched the eligibility requirements participated in this clinical study. One gram of mesalamine (t.i.d.) and a placebo were administered to the mesalamine group (n = 26) for a duration of 24 weeks. Mesalamine 1 g t.i.d. and PTX 400 mg two times daily were administered to the PTX group (n = 26) for 24 weeks. A gastroenterologist investigated patients at the start and 6 months after the medication was given to assess disease activity index (DAI) and numeric pain rating scale (NRS). Also, interleukin-6 (IL-6), sphingosine 1 phosphate (S1P), tumor necrosis factor-alpha (TNF-α), and fecal myeloperoxidase (MPO) were measured before and after therapy. Zonula occuldin-1 (ZO-1) and signal transducer and activator of transcription factor-3 (STAT-3) expression was assessed before and after therapy as well as histological assessment. Short Form 36 Health Survey (SF-36), was assessed for each patient before and after 6 months of treatment.

RESULTS:

The PTX group showed statistically lower levels of serum SIP, TNF-α, IL-6, faecal MPO, gene expression of STAT-3, and a significant increase of ZO-1 in comparison with the mesalamine group. DAI and NRS significantly decreased whereas SF-36 significantly increased in the PTX group.

CONCLUSION:

PTX could alleviate inflammation in patients with UC, so it might be promising adjunctive for patients with UC. TRIAL REGISTRATION IDENTIFIER NCT05558761.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Inflammopharmacology Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Suiza